Cannabis Report
Home > Boards > US OTC > Biotechs >

Mymetics Corporation (MYMX)

Add MYMX Price Alert      Hide Sticky   Hide Intro
Moderator: TheHungryHippo, corpus
Search This Board: 
Last Post: 8/14/2018 1:10:22 AM - Followers: 72 - Board type: Free - Posts Today: 1




Mymetics Corporation is US registered biotechnology company with its main offices in Switzerland and the Netherlands. Focused on developing next generation preventative vaccines for infectious diseases. Mymetics core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins in combination with rationally designed antigens and membrane proteins.

Mymetics currently has 5 vaccines in its pipeline:
Intranasal Influenza


Current Share Structure:

Outstanding Shares: 303.7 million (03/2018 unchanged since 2014)
Floating Shares: 91.1 million*  (a/o 03/29/16)
* verified by TA (

Market Cap (04/17/2018): $9.8 million
Enterprise Value: see link below

*Enterprise value can be thought of as the theoretical takeover price if the company were to bought. In the event of such a buyout, an acquirer would generally have to take on the company's debt, but would pocket its cash for itself. EV differs significantly from simple market capitalization in several ways, and many consider it to be a more accurate representation of a firm's value.


Mymetics Starts Research Project with Sanofi for Influenza Vaccines

Dec 01, 2016
OTC Disclosure & News Service

EPALINGES, Switzerland, Dec. 1, 2016

EPALINGES, Switzerland, Dec. 1, 2016 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (NYSE: SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics' proprietary virosome technology platform in pre-clinical settings. If this project is successful it could result in a further and more extensive collaboration between the two companies.

"We are very excited to start this initial collaboration project with Sanofi, a world leader in the vaccine industry," said Ronald Kempers, CEO of Mymetics. "We look forward to show that our proprietary virosome technology and more than 30 years of virosome vaccines expertise can make a valuable difference in improving the effectiveness and cost competitiveness of influenza vaccines."

About Mymetics
Mymetics Corp. (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious diseases. It currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya,  and the RSV vaccine. HIV, malaria and intra-nasal influenza vaccines have successfully finished Phase 1 clinical trials, while the others are in the pre-clinical phase.

Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Mymetics' vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, in combination with humoral and cellular immune responses as a second-line defense, which can be essential for the development of an effective vaccine.

Mymetics' unique approach is being validated through partnerships with leading pharmaceutical or research organizations, including projects with Sanofi, PATH-MVI and the Bill and Melinda Gates Foundation.

For further information, please visit




Intellectual  Property

WO/1999/025377 (GP41 mutee) Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection Mymetics Corp. Expiration date: November 16, 2018
WO/2005/010033 (GP41 ter) New soluble and stabilized trimeric form of GP 41 polypeptide Mymetics Corp. Expiration date: July 28, 2024
WO/2007/099446 (Virosome-P1) Virosome-like vesicles comprising gp41 - derived antigens Mymetics Corp. + INSERM + Pevion Expiration date: January 3, 2027

US/61/202 215 (GP41 4th gen) Mymetics Corp. Expiration date: February 5, 2029
US/61/202 219 (Splitting GP41) Mymetics Corp. Expiration date: February 5, 2029
WO/2004/106366 (UK39) Methods for synthetizing conformationally constrained peptides, peptidomimetics and use of such peptidomimetics as synthetic vaccines Mymetics Corp. Expiration date: June 1, 2024
WO/2004/078099 (AMA49) Compositions and methods for the generation of immune response against Malaria Mymetics Corp. Expiration date: March 2, 2023
WO/2004/045641 (APRECS) Antigen-complexes Bestewil BV Expiration date: November 19, 2023
WO/2004/110486 (Lipopeptide) Functionally reconstituted viral membranes containing adjuvant Bestewil BV Expiration date: June 17, 2024
WO/2004071492 (DCPC) Virosome-like particles Bestewil BV Expiration date: December 2, 2023
  [Viruses that can be applied and used in the formation of the virosome-like-particles according to the invention can be derived from all sorts of viruses, non-limiting examples of     such viruses being: Retroviridae such as Human Immunodeficiency virus (HIV); rubellavirus; paramyxoviridae such as parainfluenza viruses, measles, mumps, respiratory syncytial virus, human metapneumovirus; flaviviridae such as yellow fever virus, dengue virus, Hepatitis C Virus (HCV), Japanese Encephalitis Virus (JEV), tick-borne encephalitis, St. Louis encephalitis or West Nile virus; Herpesviridae such as Herpes Simplex virus, cytomegalovirus, Epstein-Barr virus; Bunyaviridae; Arenaviridae; Hantaviridae such as Hantaan; Coronaviridae; Papovaviridae such as human Papillomavirus; Rhabdoviridae such as rabies virus. Coronaviridae such as human coronavirus; Alphaviridae, Arteriviridae, filoviridae such as Ebolavirus, Arenaviridae, poxyiridae such as smallpox virus, and African Swine Fever virus.]               ,901,920.PN.&OS=PN/7,901,920&RS=PN/7,901,920



Virosomes: A Novel Strategy for Drug Delivery and Targeting


Virosomes are reconstituted viral envelopes that can serve as vaccines and as vehicle for cellular delivery of macromolecules. The prospect of drug delivery and targeting using virosomes is an interesting field of research and development. Because virosomes are biocompatible, biodegradable, nontoxic, and non-autoimmunogenic, attemps have been made to use them as vaccines or adjuvants as well as delivery systems for drugs, nucleic acids, or genes for therapeutic purposes. Influenza virus is the most common virus of choice. The success of virosomal drug delivery depends on the methods used to prepare the encapsulated bioactive materials and incorporate them into the virosomes, as are characterization and formulation of the finished preparation. Virosome technology could potentially be used to deliver peptides, nucleic acids or genes, and drugs like antibiotics, anticancer agents, and steroids.

Promising drugs are often discontinued during development because they cannot be suitably delivered to target cells, tissues, and organs. The new generation of therapeutics against cancer or neurodegenerative disorders require delivery systems that target drugs to specified cell types and host tissues by receptor-mediated uptake and contolled release. Virosomal technology presents a novel sophisticated delivery system to meet these challenges.

Virosomes are reconstituted viral envelopes, including membrane lipids and viral spike glycoproteins, but devoid of viral genetic material. The external surface of the virosome resembles that of a virus particle, with spike proteins protruding from the membrane, but their interior compartment is empty. Because virosomes display viral envelope glycoproteins, which, in their native conformation stimulate humoral responses, they are highly effective as vaccine antigens and adjuvants.10-12. Moreover, since the receptor-binding and membrane-fusion properties of the viral envelope glycoprotein can be preserved, virosomes can be used as transport vehicles for cellular delivery of biologically active macromolecules.

Overall, virosomes protect pharmaceutically active substances from proteolytic degradation and low pH within endosomes, allowing their contents to remain intact when they reach the cytoplasm.This is the major advantage of virosomal carrier systems over other drug-delivery vehicles, including liposomal and proteoliposomal carrier systems.


Advantages of Virosomal Drug Delivery

         Virosomal technology is approved by the FDA for use in humans, and has a high safety profile
         Virosomes are biodegradable, biocompatible, and non-toxic12
         No disease-transmission risk
         No autoimmunogenity or anaphylaxis10
         Broadly applicable with almost all important drugs (anticancer drugs, proteins, peptides, nucleic acids, antibiotics, fungicides)
         Enables drug delivery into the cytoplasm of target cell
         Promotes fusion activity in the endolysosomal pathway
         Protects drugs against degradation


Virosomal Structure and Modifications

Image result for influenza virosome images

Figure 1: Virosomes are reconstituted influenza virus envelopes devoid of inner core and genetic information

Virosomes are spherical unilamellar vesicles with a mean diameter of around 150 nm. Influenza virus is most commonly used for virosome production. Virosomes cannot replicate but are pure fusion-active vesicles. In contrast to liposomes, vorosomes contain functional viral envelope glycoproteins: influenza virus hemagglutinin (HA) and neuraminidase (NA) are intercalated within the phospholipid bilayer membrane (Figure 1). Further characteristics of virosomes depend on the choice of bilayer components. Virosomes can be optimized for maximal incorporation of the drug, or for the best physiological effect by modifying the content or type of membrane lipids used. It is even possible to generate carriers for antisense-oligonucleotides or other genetic molecules, depending on whether positively or negatively loaded phospholipids are incorporated into the membrane. Various ligands, such as cytokines, peptides, and monoclonal antibodies (MAbs) can be incorporated into the virosome and displayed on the virosomal surface. Even tumor-specific monoclonal antibody fragments (Fab) can be linked to virosomes to direct the carrier to selected tumor cells.1,11


Drug-Delivery Approaches

Bioactive drug compounds can be entrapped in the aqueous interior of the virosome or in the lipid membrane of the virosome for facilitated entry of the compounds into the cells.19

Virosomes are particularly useful for delivering nucleic acids or genes. These compounds are delivered into the host cell cytoplasm on fusion of the virosome with the endosome or plasma membrane.20  Nucleic acids or genes encoding a naturally occuring protein can be introduced into host cells and can be expressed, provided that the expression cassette contains the proper cis-acting regulatory elements.20,21

Drugs or nucleic acids can be incorporated into the virosome at the time of virosome preparation. The bioactive compound is typically added to the lipid-HA containing solution following removal of the nucleocapsid. Alternatively, the bioactive compound is initially incorporated into a liposome, which is then fused with a virosome containing two hemagglutinins with different pH thresholds to form a virosome-liposome hybrid.22

Proteins also can be delivered to cells via virosome. For example, the gelonin subunit A of diphitheria toxin and ovalbumin have also been successfully delivered  by virosome to target cells.15,22,23  Virosomes carrying peptides derived from the influenza nucleoprotein or intact ovalbumin induced strong cytotoxic T lymphocyte responses, which suggests that the encapsulated peptides and proteins gained access to the cytoplasm.24,25


Targeted Drug Delivery

Ideally one would like to be able to target drug delivery to selected tissues. One can tailor virosomes to targets by incorporating specific molecules (e.g. Fab fragments and ligands) into the virosome's composition. The feasibility of targeted delivery of anticancer drugs by means of virosomal carrier has been demonstrated recently by two independent approaches. In one, a MAb cross-linked to the surface of virosomes mediated specific targeting of the virosomal carrier containing an anticancer drug (e.g. doxorubicin) to human cancer cells. MAbs can bind specifically to cancer-related antigens, providing a means to target systemically administered virosomes to cancerous tissues. Alternatively, ligands that bind surface receptors on the target cells also can be bound to the virosomes to achieve targeted drug delivery. Tumors of mice treated with targeted drug-loaded virosomes failed to grow, and mortality of these animals was significantly reduced. These positive results will definitely open a new field of applications for virosomal technology.18,19


Administration of Virosomes

Several formulations have been reported. Generally, virosomes are suspended in buffered saline (135-150 mMNaCl), but other suitable vehicles also exist. These compositions should be sterilized by conventional liposomal sterilization techniques, such as membrane filtration. The formulation also generally contains auxillary substances as required to stimulate physiological conditions, such as buffering agents and isotonicity adjusting agents (sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride).12,17  The concentration of virosomes used in the vehicle ranges from 20-200mg/ml. These concentrations are varied to optimize treatment with different virosome components or for particular purposes.19

The virosomes are administered in a variety of parenteral routes, including intravenous, intramuscular, subcutaneous, inta-arterial, and inhalable delivery. In addition, virosomes can be administered topically, orally, or transdermally. The virosomes also can be incorporated into implantable devices for long-term release.19,21,22


Authors :  Mazumder B., Bhattacharya S.

1.    Almeida JD, Brand CM, Edwards DC, Heath TD. Formation of virosomes from influenza subunits and liposomes. Lancet 1975; 2:899-901
10.  Gluck R, Mschler R, Finkel B, Que JU, Scarpa B, Cryz SJ. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet, 1994;344:160-3
11.  Huckriede A, Bungener L, Veer W, Holtrop M, Daemen T, Palache AM, Wilschut J. Influenza virosomes: combining optimal presentation of hemagglutinin with                  
       immunopotentiating activity. Vaccine, 2003;21:925-31
12.  Huckriede A, Burgener L, Stegmann T, Daemen T, Medema J, Palache AM, Wilschut J. The virosome concept for influenza vaccines. Vaccine 2005;23(s1):S26-38
15.  Bron R, Ortiz A, Wilschut J.  Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (Virosomes). Biochem, 1994;33:9110-17
17.  Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM. The virosome concept for influenza vaccines. Vaccine. 2005;23:S26-38
18.  Felnerova D, Viret JF, Gluck R, Moser C.  Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 2004;15:518-29
19.  Cusi MG.  Application of influenza virosomes as a delivery system. Human Vaccines. 2006;2:1-7
20.  Daemen T, de Mare A, Bungener L, de Jonge J, Huckriede A, Wilschut J.  Virosomes for antigen and DNA delivery.  Adv Drug Deliv. Rev.2005;57:451-63
21.  Sarkar DP, Ramani K, Tyagi SK.  Targeted gene delivery by virosomes.  Methods Mol Biol. 2002;199:163-73
22.  Schoen P, Chonn A, Cullis PR, Wilschut J, Scherrer P.  Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene 
       Ther. 1999;6:823-32.





OTC Disclosure & News Service

Release Date
April 23, 2018

Press Release
Dec 1, 2016 Mymetics Starts Research Project with Sanofi for Influenza Vaccines Press Release
Sep 19, 2016 Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development Press Release
Apr 11, 2016 Mymetics' HIV Vaccine Candidate Confirms Promise in Preclinical Study With the Texas Biomedical Research Institute Press Release
Apr 5, 2016 Mymetics Announces Successful Preclinical Results With Malaria Transmission-Blocking Vaccine Candidate Press Release
Jan 28, 2016 Mymetics Announces Discontinuation of the RSV Collaborative Project Press Release
Apr 20, 2015 Mymetics' led consortium awarded Euro 8.4 million to develop thermo stable and cold chain independent vaccines Press Release
Jan 2, 2015 OTC Markets Group Welcomes Newly Verified OTCQB Companies – Jan. 2 Announcement
Nov 18, 2014 Mymetics Announces New Collaboration to Advance the Development of an Innovative Malaria Vaccine Candidate Press Release
Sep 29, 2014 Mymetics' Promising HIV Vaccine Candidate Obtains Funding to Begin Study at Texas Biomedical Research Institute Press Release




Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MYMX News: Quarterly Report (10-q) 08/13/2018 09:06:12 AM
MYMX News: Quarterly Report (10-q) 05/14/2018 02:13:13 PM
MYMX News: Current Report Filing (8-k) 04/23/2018 06:11:53 AM
MYMX News: Annual Report (10-k) 03/29/2018 12:24:30 PM
News News Alert: Quarterly Report (10-q) 08/13/2018 09:06:12 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#7598  Sticky Note Spray drying of virosomes to produce stable vaccines TheHungryHippo 08/03/18 05:13:18 PM
#5685  Sticky Note Copy of MACIVIVA Presentation at World Vaccine Congress corpus 01/09/18 12:36:16 PM
#7902   Maybe but dd is here somehow unclear Trompete 08/14/18 01:10:22 AM
#7901   They know we can't do the push to Work Harder 08/13/18 10:35:35 PM
#7900   Yep, the collaboration here is just fantastic Work Harder 08/13/18 10:33:20 PM
#7899   We know what Hedge Funders like to do bow-tie 08/13/18 10:28:41 PM
#7898   Mario is staying busy... Positive Delegate Experiences at BOS Staypositive1 08/13/18 10:09:47 PM
#7897   Marcuard Family Office is listed as a hedge fund Work Harder 08/13/18 09:57:43 PM
#7896   More of those double double secrets. . RESULTS Physical and Biochemical Staypositive1 08/13/18 09:55:34 PM
#7895   As we talked earlier. Why do the Staypositive1 08/13/18 09:47:54 PM
#7894   Yep! It's probably in there Bro!! Double 5 Secret bow-tie 08/13/18 09:38:24 PM
#7893   Cuz it's not there but Work Harder 08/13/18 09:30:02 PM
#7892   Did'nt catch it Bro!! bow-tie 08/13/18 09:28:35 PM
#7891   They don't say what's in the gel or Work Harder 08/13/18 09:25:16 PM
#7890   Harry Wickey, I got a feeling all the bow-tie 08/13/18 09:19:30 PM
#7889   Bow-tie, Harry Wickey 08/13/18 09:07:24 PM
#7888   This was done at the National Institutes Of bow-tie 08/13/18 08:56:28 PM
#7887   Latest News on Dr. Ruth Ruprecht: bow-tie 08/13/18 08:22:13 PM
#7886   The DD says otherwise. Staypositive1 08/13/18 04:10:54 PM
#7885   Maybe there is no success therefore Trompete 08/13/18 03:41:13 PM
#7884   Seems Mymetics doesnt like to tout any success. Staypositive1 08/13/18 03:32:58 PM
#7883   Maciviva partner Upperton: Phosphene 08/13/18 03:28:29 PM
#7882   I'm happy w/ the action Work Harder 08/13/18 02:55:17 PM
#7881   It doesn't appear the ploy for cheap shares Phosphene 08/13/18 02:52:54 PM
#7880   Abberration for sure. Phosphene 08/13/18 02:44:19 PM
#7879   That's about 5k bucks... It's literally nothing Trompete 08/13/18 02:30:48 PM
#7878   Right, who's best interest is it in not Work Harder 08/13/18 02:22:23 PM
#7877   I like the 10-Q. Best for awhile. Harry Wickey 08/13/18 02:21:32 PM
#7876   OTCX and the boys are playing games. Staypositive1 08/13/18 02:20:06 PM
#7875   Down 20% on 109k shares with direction provided Phosphene 08/13/18 02:19:54 PM
#7874   Really? With such volume this drop? ?? Trompete 08/13/18 02:17:37 PM
#7873   That is an understatement. Staypositive1 08/13/18 01:31:51 PM
#7872   Kemper's instead of working against your investors work bow-tie 08/13/18 01:22:31 PM
#7871   Funder's will get a return on their money Phosphene 08/13/18 01:19:30 PM
#7870   The Company intends to continue to incur additional Phosphene 08/13/18 01:12:20 PM
#7869   Renamed Hyposwiss Private Bank Genève S.A. and acting Phosphene 08/13/18 01:10:17 PM
#7868   Sanofi details in Oct: :) bow-tie 08/13/18 12:33:04 PM
#7867   Funders gave them more money. and Giving them TheHungryHippo 08/13/18 11:40:17 AM
#7866   Lol wait for me, I incredible spike hahahhaha Trompete 08/13/18 11:19:35 AM
#7865   Good morning! From 10-Q: corpus 08/13/18 10:41:10 AM
#7864   Outta here Work Harder 08/13/18 09:59:56 AM
#7863   2022 dead ahead Work Harder 08/13/18 09:54:08 AM
#7862   Maciviva project). This project will end by October Work Harder 08/13/18 09:47:00 AM
#7861   It's a killer Work Harder 08/13/18 09:44:53 AM
#7860   The Q is out Profit 08/13/18 09:26:27 AM
#7859   One thing for sure Bro Work Harder 08/12/18 09:08:40 PM
#7858   LMAO BRO!! On the sleeping clip not what bow-tie 08/12/18 08:56:19 PM
#7857   Martin Burkhardt bow-tie 08/12/18 08:54:28 PM
#7856   Sleeping beauty Work Harder 08/12/18 08:53:52 PM
#7855   Yep! Sanofi has been here all along!! :) bow-tie 08/12/18 08:49:52 PM
#7854   & Back in 2011 roughly Work Harder 08/12/18 08:46:54 PM
#7853   Dr. Toon Stegmann Work Harder 08/12/18 08:45:36 PM